« Back to the previous page

Also available in:

Buyer for a biologics CRO in Europe

Company to buy

  • Size: Medium-sized
  • Revenue: 5-25 million EUR
  • Location of the target company: Europe 
  • Reason for acquisition: The company wants to acquire a biologics CRO company to expand the company’s operations in Europe
  • #CFIE PHB135

Overview of this buyer for a biologics CRO in Europe

This buyer is a large contract research organization engaged in the research of new drugs and product development. The company is interested in expanding its operations through the acquisition of a suitable CRO company in Europe.

Profile (strategy) of this buyer for a biologics CRO in Europe

The buyer is a large company with more than 15 years of history providing data-driven solutions. The company provides many services in different segments such as bioanalytical, bioequivalence, CMC, drug metabolism and pharmacokinetics (DMPK), and safety and toxicology services. The company has operations in North America and Asia, the two largest CRO markets in the world allowing the company to be closer to its partners. While developing new molecules and new solutions for the biggest pharmaceutical companies around the world and operating in these two markets, it also helps the companies to file regulatory submissions to the FDA in the USA, and the relevant authorities in China and other countries. The company has a presence worldwide with more than 700 employees and about 100 million EUR in revenue. 

Sell your biologics CRO company in Europe

Contact us to get details about this buyer for a biologics CRO in Europe

Activities and products of the target 

The buyer is looking for a CRO company in Europe, especially in Germany, the Netherlands, Belgium, or Switzerland, but will consider other locations. An interesting company to this buyer would be a medium-sized CRO company specialized in biologics/analytical, pre-clinical, DMPK, or CMC. The company should have more than a 10% EBITDA margin and be profitable.

Highlights of this buyer for a biologics CRO in Europe

  • More than 20 years of history
  • Stock listed company
  • Revenue of 100 million EUR
  • Market leader
  • Worldwide presence

Information about this buyer for a biologics CRO in Europe

Feel free to contact us for more information regarding this buyer for a biologics CRO in Europe or if you know possible interested or suitable parties. For more buyers for a biologics CRO in Europe, please visit the section pharmaceutical companies wanted. For pharmaceutical firms for sale visit the section pharmaceutical companies for sale

Note: CFIE only works with formal companies. We do get a lot of requests and it is difficult to follow up on all inquiries from visitors to our website. For each company we assess the likelihood of a future transaction. We only get back to you if we see a realistic opportunity to do a future acquisition or business sale. In order to increase your chances of receiving a reply as an individual please explain as much as possible about your personal background strategy and fit with the target. There is also a possibility that your details will be kept on file and we will get back to you once there is an opportunity to do a transaction. CFIE can’t guarantee you will receive an answer to your request.